Literature DB >> 35942856

Gambiense human African trypanosomiasis: the bumpy road to elimination.

Epco Hasker1, Andrew Hope2, Emmanuel Bottieau3.   

Abstract

PURPOSE OF REVIEW: Gambiense human African trypanosomiasis (gHAT), a disease that has killed hundreds of thousands as recently as the 1990s, could be on the verge of elimination or even eradication. This review describes recent developments that give us reasons for optimism as well as some caveats. RECENT
FINDINGS: New developments in diagnostic and vector control tools, and especially in treatment, make it possible to strive for elimination of transmission of gHAT by 2030, perhaps even eradication.
SUMMARY: Gambiense human African trypanosomiasis is a deadly infectious disease affecting West and Central Africa, South Sudan and Uganda, and transmitted between humans by tsetse flies. The disease has caused several major epidemics, the latest one in the 1990s. Thanks to recent innovations such as rapid diagnostic tests for population screening, a single-dose oral treatment and a highly efficient vector control strategy, interruption of transmission of the causative parasite is now within reach. If indeed gHAT has an exclusively human reservoir, this could even result in eradication of the disease. Even if there were an animal reservoir, on the basis of epidemiological data, it plays a limited role. Maintaining adequate postelimination surveillance in known historic foci, using the newly developed tools, should be sufficient to prevent any future resurgence.
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2022        PMID: 35942856      PMCID: PMC9553258          DOI: 10.1097/QCO.0000000000000860

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.968


  49 in total

1.  New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice.

Authors:  Andreas K Lindner; Veerle Lejon; François Chappuis; Jorge Seixas; Leon Kazumba; Michael P Barrett; Erick Mwamba; Olema Erphas; Elie A Akl; Gemma Villanueva; Hanna Bergman; Pere Simarro; Augustin Kadima Ebeja; Gerardo Priotto; Jose Ramon Franco
Journal:  Lancet Infect Dis       Date:  2019-12-23       Impact factor: 25.071

Review 2.  The treatment of human African trypanosomiasis.

Authors:  J Pépin; F Milord
Journal:  Adv Parasitol       Date:  1994       Impact factor: 3.870

3.  The importance of 2,3-dimercaptopropinol (British anti-lewisite, BAL) in the trypanocidal activity of topical melarsoprol.

Authors:  F W Jennings; J M Atouguia; M Murray
Journal:  Acta Trop       Date:  1996-10       Impact factor: 3.112

4.  Integration of diagnosis and treatment of sleeping sickness in primary healthcare facilities in the Democratic Republic of the Congo.

Authors:  P Mitashi; E Hasker; F Mbo; J P Van Geertruyden; M Kaswa; C Lumbala; M Boelaert; P Lutumba
Journal:  Trop Med Int Health       Date:  2014-10-20       Impact factor: 2.622

5.  Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad).

Authors:  Mahamat Hissene Mahamat; Mallaye Peka; Jean-Baptiste Rayaisse; Kat S Rock; Mahamat Abdelrahim Toko; Justin Darnas; Guihini Mollo Brahim; Ali Bachar Alkatib; Wilfrid Yoni; Inaki Tirados; Fabrice Courtin; Samuel P C Brand; Cyrus Nersy; Idriss Oumar Alfaroukh; Steve J Torr; Mike J Lehane; Philippe Solano
Journal:  PLoS Negl Trop Dis       Date:  2017-07-27

6.  Impact of tiny targets on Glossina fuscipes quanzensis, the primary vector of human African trypanosomiasis in the Democratic Republic of the Congo.

Authors:  Inaki Tirados; Andrew Hope; Richard Selby; Fabrice Mpembele; Erick Mwamba Miaka; Marleen Boelaert; Mike J Lehane; Steve J Torr; Michelle C Stanton
Journal:  PLoS Negl Trop Dis       Date:  2020-10-16

7.  Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study.

Authors:  Victor Kande Betu Ku Mesu; Wilfried Mutombo Kalonji; Clélia Bardonneau; Olaf Valverde Mordt; Digas Ngolo Tete; Séverine Blesson; François Simon; Sophie Delhomme; Sonja Bernhard; Hélène Mahenzi Mbembo; Christian Mpia Moke; Steven Lumeya Vuvu; Junior Mudji E'kitiak; Felix Akwaso Masa; Melchias Mukendi Ilunga; Dieudonné Mpoyi Muamba Nzambi; Tim Mayala Malu; Serge Kapongo Tshilumbwa; Franck Botalema Bolengi; Mathieu Nkieri Matsho; Crispin Lumbala; Bruno Scherrer; Nathalie Strub-Wourgaft; Antoine Tarral
Journal:  Lancet Glob Health       Date:  2021-07       Impact factor: 26.763

Review 8.  Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?

Authors:  Philippe Büscher; Jean-Mathieu Bart; Marleen Boelaert; Bruno Bucheton; Giuliano Cecchi; Nakul Chitnis; David Courtin; Luisa M Figueiredo; José-Ramon Franco; Pascal Grébaut; Epco Hasker; Hamidou Ilboudo; Vincent Jamonneau; Mathurin Koffi; Veerle Lejon; Annette MacLeod; Justin Masumu; Enock Matovu; Raffaele Mattioli; Harry Noyes; Albert Picado; Kat S Rock; Brice Rotureau; Gustave Simo; Sophie Thévenon; Sandra Trindade; Philippe Truc; Nick Van Reet
Journal:  Trends Parasitol       Date:  2018-01-23

9.  Performance of the SD BIOLINE® HAT rapid test in various diagnostic algorithms for gambiense human African trypanosomiasis in the Democratic Republic of the Congo.

Authors:  Crispin Lumbala; Paul R Bessell; Pascal Lutumba; Sylvain Baloji; Sylvain Biéler; Joseph M Ndung'u
Journal:  PLoS One       Date:  2017-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.